Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
劳拉替尼治疗晚期 ROS1+ 非小细胞肺癌：IFCT-1803 LORLATU 研究结果
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100418
Girard, N; Galland-Girodet, S; Avrillon, V; Besse, B; Duruisseaux, M; Cadranel, J; Otto, J; Prevost, A; Roch, B; Bennouna, J; Bouledrak, K; Coudurier, M; Egenod, T; Lamy, R; Ricordel, C; Moro-Sibilot, D; Odier, L; Tillon-Strozyk, J; Zalcman, G; Missy, P; Westeel, V; Baldacci, S
